Clinicopathological Significance of Mesothelin Expression in Invasive Breast Cancer

Abstract

OBJECTIVES: This study evaluated the expression profile of the mesothelin (MSLN) gene and its prognostic significance in breast cancer. METHODS: To evaluate the diagnostic and prognostic significance of mesothelin, immunohistochemistry was used to assess the level of mesothelin protein in surgically resected, formalin-fixed, paraffin-embedded invasive breast carcinoma specimens. Associations between mesothelin and other biomarkers, including oestrogen receptor (OR), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu), were also evaluated. RESULTS: A total of 182 breast carcinoma specimens were included. Mesothelin protein was present in the membrane of malignant cells. There was correlation between the presence of mesothelin in tumour cells and tumour infiltration of the lymph node. There was no correlation between the presence of mesothelin and HER2/neu protein, OR and PR in tumour cells. Mesothelin levels were significantly associated with decreased overall survival. CONCLUSIONS: Lymph node status, tumour size, HER2/neu and mesothelin protein levels in breast cancer cells were independent prognostic factors. Mesothelin could be useful as a prognostic marker of overall survival in invasive breast cancer.

Keywords

BREAST CANCER METASTASIS MESOTHELIN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2/NEU)OESTROGEN RECEPTOR PROGESTERONE RECEPTOR LYMPH NODE OVERALL SURVIVAL

References

Vivanco

: Biomarkers in breast cancer. Methods Mol Biol 2010; 593: 137–156.

: Development and trends of surgical modalities for breast cancer in China: A review of 16-year data. Ann Surg Oncol 2007; 14: 2502–2509.

Maskarinec

Sen

Koga

: Ethnic differences in breast cancer survival: status and determinants. Womens Health (Lond Engl) 2011; 7: 677–687.

Chang

Pastan

: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996; 93: 136–140.

Chang

Pastan

Willingham

: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992; 50: 373–381.

Rump

Morikawa

Tanaka

: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004; 279: 9190–9198.

Hassan

Laszik

Lerner

: Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005; 124: 838–845.

Argani

Iacobuzio-Donahue

Ryu

: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862–3868.

Uehara

Matsuoka

Tsubura

: Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 2008; 6: 186–193.

10.

Francis

Beadle

Thomas

: Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Pathology 2006; 38: 391–398.

11.

Ménard

Fortis

Castiglioni

: HER2 as a prognostic factor in breast cancer. Oncology 2001; 61 (suppl 2): 67–72.

12.

Guarneri

Giovannelli

Ficarra

: Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13: 838–844.

13.

Ivkovic-Kapicl

Knezevic-Usaj

Djilas-Ivanovic

: Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. In Vivo 2007; 21: 673–678.

14.

Ordóñez

: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192–197.

15.

Hassan

Kreitman

Pastan

: Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005; 13: 243–247.

16.

Ordóñez

: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003; 27: 1418–1428.

17.

Rizk

Servais

Tang

: Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2012; 21: 482–486.

18.

Bera

Pastan

: Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000; 20: 2902–2906.

19.

Yen

Hsu

Mao

: Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006; 12: 827–831.

20.

Baba

Ishigami

Arigami

: Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 2012; 105: 195–199.

21.

Galloway

Murray

Moffat

: The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies. Histopathology 2006; 48: 767–769.

22.

Gubbels

Belisle

Onda

: Mesothelin—MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006; 5: 50.

23.

Prieve

Moon

: Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC Dev Biol 2003; 3: 2.

24.

Ciocca

Gago

Fanelli

: Coexpression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications. J Steroid Biochem Mol Biol 2006; 102: 32–40.

25.

Cao

Zhang

Liu

: High-level SLP-2 expression and HER2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol 2007; 128: 430–436.